GEORGE R BLUMENSCHEIN to Quinolines
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Quinolines.
Connection Strength
0.371
-
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs. 2013 Apr; 31(2):417-24.
Score: 0.322
-
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91.
Score: 0.049